Recombinant Human IL-2Rα

Recombinant Human IL-2Rα is used in research applications to modulate and study IL-2 signaling, enhance immune cell responses, and investigate mechanisms of immune regulation, particularly in T cell biology and immunotherapy contexts.

Key scientific reasons to use Recombinant Human IL-2Rα:

• Modulation of IL-2 Signaling: IL-2Rα (CD25) is the high-affinity component of the IL-2 receptor complex. Its presence increases the sensitivity of cells to IL-2, allowing for more robust and sustained IL-2 signaling even after cytokine withdrawal. This is crucial for experiments aiming to dissect temporal aspects of IL-2 signaling or to boost T cell responses in competitive environments.

• Enhancement of Immune Responses: Soluble IL-2Rα (sIL-2Rα) can facilitate IL-2–mediated immune responses by enhancing downstream signaling events such as Stat5 phosphorylation and Foxp3 expression in CD4+ T cells. This property is valuable for studies on T cell proliferation, regulatory T cell (Treg) induction, and immune modulation.

• Creation of Cytokine Reservoirs: Recombinant IL-2Rα can act similarly to membrane-bound receptors by creating extracellular reservoirs of IL-2, increasing cytokine stability and potentially altering pharmacokinetics in vitro and in vivo. This can be leveraged to study cytokine availability and receptor recycling mechanisms.

• Modeling Disease and Therapy: Elevated levels of IL-2Rα are associated with disease progression in certain cancers and autoimmune conditions. Using recombinant IL-2Rα allows researchers to model these disease states, investigate therapeutic interventions, and understand the impact of receptor expression on immune cell competition and persistence.

• Adoptive Cell Therapy Research: In adoptive T cell transfer models, IL-2Rα expression on donor cells provides a competitive advantage for IL-2 therapy, especially in lymphoreplete environments where host cells compete for cytokines. Recombinant IL-2Rα can be used to optimize protocols for enhancing donor cell persistence and anti-tumor efficacy.

Typical applications include:

• In vitro assays of T cell activation, proliferation, and differentiation.
• Studies of regulatory T cell (Treg) induction and function.
• Investigations into cytokine-receptor interactions and signaling pathways.
• Preclinical models of cancer immunotherapy and autoimmune disease.

Best practices:

• Use recombinant IL-2Rα in combination with IL-2 to study synergistic effects on immune cell signaling and function.
• Carefully titrate concentrations to model physiological or pathological conditions.
• Employ appropriate controls to distinguish effects mediated by IL-2Rα from those of IL-2 alone.

In summary, Recombinant Human IL-2Rα is a powerful tool for dissecting and manipulating IL-2-driven immune responses, with broad utility in immunology, oncology, and translational research.

You can use recombinant human IL-2Rα as a standard for quantification or calibration in your ELISA assays, provided that the recombinant protein is of high purity, its concentration is accurately known, and it is compatible with the antibodies and detection system used in your assay.

Key considerations and supporting details:

• Compatibility: Most commercial ELISA kits for human IL-2Rα (CD25) are designed to recognize both natural and recombinant forms of the protein, and their standard curves are typically generated using recombinant human IL-2Rα. This ensures that the recombinant standard will be detected equivalently to the native protein in your samples.

• Calibration and Quantification: The recombinant standard should be reconstituted and diluted according to the kit or assay protocol to generate a standard curve covering the expected concentration range in your samples. The standard curve allows for accurate quantification of IL-2Rα in unknown samples by interpolation.

• Validation: It is important to confirm that the dose-response curve generated with your recombinant standard is parallel to the curve obtained with the kit’s reference standard (if available) and with natural IL-2Rα, ensuring equivalent immunoreactivity. Parallelism indicates that the recombinant standard is suitable for quantification.

• Purity and Concentration: Use a recombinant IL-2Rα preparation with high purity (typically >95%) and a well-characterized concentration. Impurities or inaccurate concentration assignment can lead to errors in quantification.

• Documentation: For publication or regulatory purposes, document the source, lot, and characterization of the recombinant standard used, as well as any validation data (e.g., parallelism, recovery, linearity).

Limitations:

• If your ELISA kit is calibrated against a specific reference material (e.g., NIBSC 97/600), ensure your recombinant standard is comparable or perform cross-validation.
• Always follow the manufacturer’s recommendations for standards and controls to ensure assay reliability and reproducibility.

In summary, recombinant human IL-2Rα is widely accepted as a standard for ELISA quantification, provided it is validated for your specific assay system and meets quality criteria.

Recombinant Human IL-2Rα (CD25) has been validated in published research for applications including ELISA (as a calibrator or standard), bioassays measuring IL-2-dependent cell proliferation, and studies of immune activation and regulation.

Key validated applications include:

• ELISA (Enzyme-Linked Immunosorbent Assay):

  • Used as a calibrator or standard for quantifying soluble IL-2Rα in human serum and other biological fluids.
  • Measurement of soluble IL-2Rα levels is correlated with immune activation and is used in studies of inflammatory conditions, leukemias, lymphomas, and autoimmune diseases.

• Bioassays:

  • Employed to assess the ability of recombinant IL-2Rα to inhibit IL-2-dependent proliferation of cell lines such as MO7e human megakaryocytic leukemic cells.
  • Used to study the functional interaction between IL-2 and its receptor, including the formation of high-affinity receptor complexes and downstream signaling.

• Immune Activation and Regulation Studies:

  • Investigated for its role in modulating T and B cell activation, as increased soluble IL-2Rα levels are associated with immune system activation.
  • Utilized in research on the regulation of T cell responses, particularly in the context of autoimmune diseases and cancer immunotherapy.

Additional relevant details:

• Mechanistic Studies: Recombinant IL-2Rα is used to dissect the molecular interactions between IL-2 and its receptor subunits, including studies on receptor affinity, signaling pathways, and receptor masking strategies for targeted immunotherapy.
• Clinical Biomarker Research: Elevated soluble IL-2Rα is a biomarker for immune activation in various diseases, and recombinant forms are essential for assay development and validation.
• Combination Immunotherapy: Recombinant IL-2Rα has been incorporated into engineered cytokine therapies, such as receptor-masked IL-2 immunocytokines, to enhance specificity and reduce toxicity in cancer models.

In summary, published research validates recombinant human IL-2Rα for use in ELISA, bioassays, immune activation studies, mechanistic receptor research, and as a tool in developing targeted immunotherapies.

To reconstitute and prepare Recombinant Human IL-2Rα protein for cell culture experiments, dissolve the lyophilized protein in sterile deionized water to a concentration of 0.1–1.0 mg/mL. Gently mix by swirling or tapping; avoid vigorous shaking or vortexing to prevent foaming and protein denaturation.

Step-by-step protocol:

• Centrifuge the vial briefly before opening to ensure all powder is at the bottom.
• Add sterile deionized water (or sterile water for injection) to achieve the desired concentration (typically 0.1–1.0 mg/mL).
• Gently mix until fully dissolved. Do not shake or vortex; swirl or tap gently.
• For long-term storage, aliquot the reconstituted protein and store at ≤ –20°C. For added stability, dilute with a carrier protein solution (e.g., 0.1% BSA, 10% FBS, or 5% HAS) before freezing.
• If using in serum-free culture or in vivo, avoid animal-derived carrier proteins; use trehalose as a stabilizer if needed.
• For working solutions, further dilute the stock in cell culture medium or buffer containing carrier protein to minimize adsorption and degradation.

Additional best practices:

• Always use sterile technique to prevent contamination.
• Avoid repeated freeze-thaw cycles by aliquoting into single-use volumes.
• If required, add glycerol (5–50%) for enhanced stability during long-term storage at –20°C to –80°C.
• For immediate use, store reconstituted protein at 2–8°C for up to one week.

Summary Table:

Always consult the specific product datasheet or Certificate of Analysis for any manufacturer-specific recommendations.